An interventional study of Zylox Peripheral Venous Stent and Zilver Vena Venous Stent in Iliac Vein Stenosis and Iliac Vein Occlusion, sponsored by Zhejiang Zylox Medical Device Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-23.
Sponsored by Zhejiang Zylox Medical Device Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Constriction, Pathologic with a site in China — 37 open to participants now, 40 under way, 3 of them phase 3. Constriction, Pathologic · China.
Among the 81 studies in Constriction, Pathologic with a site in China, this one is the 18th largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2020, is one of 48 with no phase, and was the 27th registered.
457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.
Browse Constriction, Pathologic studies →37 of the 81 studies in Constriction, Pathologic with a site in China are open now. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Ages 18–80
General Hospital of Shenyang Military Region · Sites in China
Ages 40+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
Xin Lou · Sites in China
Ages 18–90
The Second Hospital of Anhui Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 5 · Phase 4 1
First in 2008; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 72 across 296 interventional studies indexed under Constriction, Pathologic.
Median enrollment 145 across the 56 interventional studies, 400 across the 25 observational. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 81 have an industry lead sponsor. The 10 most frequent:
Zhejiang Zylox Medical Device Co., Ltd. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Zhejiang Zylox Medical Device Co., Ltd. has 1 study filed under Constriction, Pathologic — fewer than ten, so there is no comparison to draw.
15 of the studies in Constriction, Pathologic with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07197970Phase 3Beijing Tiantan HospitalDrug- Eluting Stent for Symptomatic Intracranial Arterial Stenosis | 2027-05-15 |
| NCT07542938Xuanwu Hospital, BeijingMedeliver Intracranial Drug Coated Balloon Catheter for Symptomatic Intracranial Atherosclerotic Stenosis | 2026-11-30 |
| NCT07462546General Hospital of Shenyang Military RegionTranscranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS) | 2026-11-30 |
| NCT06503692DK Medical Technology (Suzhou) Co., Ltd.Scoring Balloon and High Pressure Balloon in the Treatment of Arteriovenous Graft Stenosis | 2026-12 |
| NCT06539689FrontAce Scientific Co., LtdA Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries | 2026-12-04 |
Add all 15 to your calendar (.ics) → With an account.
Among the 81 studies in Constriction, Pathologic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical study on safety and efficacy of Zylox peripheral venous stent system in the treatment of iliac vein stenosis or occlusion.
The purpose of this study was to evaluate the safety and efficacy of Zylox peripheral venous stent system in the treatment of iliac vein stenosis or occlusive lesions compare with conventional venous stent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Percutaneous stent placement in the iliofemoral veins
Device: Zylox Peripheral Venous Stent
Percutaneous stent placement in the iliofemoral veins
Device: Zilver Vena Venous Stent
Self-expanding stent implantation during the index procedure.
Self-expanding stent implantation during the index procedure.
Target vascular patency rate at 12 months after operation
Target vascular patency rate
Time frame: 12 months
The incidence of major adverse events
Related to death of clinical trials
Time frame: 12 months
Adverse Event
Adverse medical events,whether or not related to the medical device
Time frame: Preoperative、Intraoperative、up to 1 month、3 month、6 month、12 month、2 years、3 years、5 years
Ran from Oct 2020 to primary completion in Oct 2023, 36 months.
Of 43 industry-sponsored interventional studies with no phase under Constriction, Pathologic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's 36 months is close to that.
Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhejiang Zylox Medical Device Co., Ltd.